- Home
- RNXT vs LSTA Comparison
RNXT vs LSTA Comparison
Compare RNXT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- LSTA
- Stock Information
- Founded
- RNXT 2012
- LSTA 1980
- Country
- RNXT United States
- LSTA United States
- Employees
- RNXT N/A
- LSTA N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- RNXT Health Care
- LSTA Health Care
- Exchange
- RNXT Nasdaq
- LSTA Nasdaq
- Market Cap
- RNXT 44.6M
- LSTA 22.3M
- IPO Year
- RNXT 2021
- LSTA N/A
- Fundamental
- Price
- RNXT $1.26
- LSTA $2.30
- Analyst Decision
- RNXT Strong Buy
- LSTA Strong Buy
- Analyst Count
- RNXT 2
- LSTA 2
- Target Price
- RNXT $7.50
- LSTA $23.50
- AVG Volume (30 Days)
- RNXT 626.0K
- LSTA 21.8K
- Earning Date
- RNXT 11-12-2025
- LSTA 11-11-2025
- Dividend Yield
- RNXT N/A
- LSTA N/A
- EPS Growth
- RNXT N/A
- LSTA N/A
- EPS
- RNXT N/A
- LSTA N/A
- Revenue
- RNXT $662,000.00
- LSTA $1,070,000.00
- Revenue This Year
- RNXT $2,988.37
- LSTA N/A
- Revenue Next Year
- RNXT $300.60
- LSTA N/A
- P/E Ratio
- RNXT N/A
- LSTA N/A
- Revenue Growth
- RNXT N/A
- LSTA N/A
- 52 Week Low
- RNXT $0.75
- LSTA $1.87
- 52 Week High
- RNXT $1.69
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- RNXT 59.62
- LSTA 47.19
- Support Level
- RNXT $1.06
- LSTA $2.11
- Resistance Level
- RNXT $1.45
- LSTA $2.33
- Average True Range (ATR)
- RNXT 0.12
- LSTA 0.17
- MACD
- RNXT 0.03
- LSTA 0.00
- Stochastic Oscillator
- RNXT 65.45
- LSTA 42.59
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.